AP2014008139A0 - Acrylamide compounds as histamine H3 receptor ligands - Google Patents

Acrylamide compounds as histamine H3 receptor ligands

Info

Publication number
AP2014008139A0
AP2014008139A0 AP2014008139A AP2014008139A AP2014008139A0 AP 2014008139 A0 AP2014008139 A0 AP 2014008139A0 AP 2014008139 A AP2014008139 A AP 2014008139A AP 2014008139 A AP2014008139 A AP 2014008139A AP 2014008139 A0 AP2014008139 A0 AP 2014008139A0
Authority
AP
ARIPO
Prior art keywords
histamine
receptor ligands
acrylamide compounds
acrylamide
compounds
Prior art date
Application number
AP2014008139A
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Adi Reddy Dwarampudi
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of AP2014008139A0 publication Critical patent/AP2014008139A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AP2014008139A 2012-08-23 2012-12-05 Acrylamide compounds as histamine H3 receptor ligands AP2014008139A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3464CH2012 2012-08-23
PCT/IN2012/000796 WO2014030170A1 (fr) 2012-08-23 2012-12-05 Composés acrylamides utilisés comme ligands des récepteurs h3 à l'histamine

Publications (1)

Publication Number Publication Date
AP2014008139A0 true AP2014008139A0 (en) 2014-12-31

Family

ID=54187093

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014008139A AP2014008139A0 (en) 2012-08-23 2012-12-05 Acrylamide compounds as histamine H3 receptor ligands

Country Status (27)

Country Link
US (1) US9328092B2 (fr)
EP (1) EP2888243B1 (fr)
JP (1) JP5981654B2 (fr)
KR (1) KR101707343B1 (fr)
CN (1) CN104540812B (fr)
AP (1) AP2014008139A0 (fr)
AU (1) AU2012388383C1 (fr)
BR (1) BR112015001524B1 (fr)
CA (1) CA2878217C (fr)
CY (1) CY1118035T1 (fr)
DK (1) DK2888243T3 (fr)
EA (1) EA025136B1 (fr)
ES (1) ES2592819T3 (fr)
HK (1) HK1204620A1 (fr)
HR (1) HRP20161167T1 (fr)
HU (1) HUE030901T2 (fr)
IL (1) IL236437A (fr)
LT (1) LT2888243T (fr)
ME (1) ME02519B (fr)
MX (1) MX360001B (fr)
PL (1) PL2888243T3 (fr)
PT (1) PT2888243T (fr)
RS (1) RS55158B1 (fr)
SG (1) SG11201408423XA (fr)
SI (1) SI2888243T1 (fr)
SM (1) SMT201600336B (fr)
WO (1) WO2014030170A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11313246B2 (en) * 2016-11-30 2022-04-26 General Electric Company Gas turbine engine wash system
WO2022113008A1 (fr) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Antagonistes/agonistes inverses du récepteur h3 de l'histamine pour le traitement d'un trouble du spectre autistique
WO2023166351A1 (fr) * 2022-03-02 2023-09-07 杭州百诚医药科技股份有限公司 Antagoniste du récepteur h3 de l'histamine et son utilisation médicale

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526518A1 (fr) * 2003-06-12 2004-12-23 Novo Nordisk A/S Derives de 1-aryl-4-(aryloxycarbonyl)-piperazine utilises en tant qu'inhibiteurs de la lipase hormonosensible
US8008301B2 (en) 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
ES2299074T3 (es) 2004-06-02 2008-05-16 F. Hoffmann-La Roche Ag Derivados de naftaleno utiles como ligandos del receptor 3 de la histamina.
WO2005123716A1 (fr) * 2004-06-21 2005-12-29 F. Hoffmann-La Roche Ag Derives d'indole utilises comme antagonistes du recepteur de l'histamine
BRPI0514553A (pt) 2004-08-23 2008-06-17 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
AU2006319232B2 (en) * 2005-11-30 2012-09-13 F. Hoffmann-La Roche Ag 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as H3 modulators
JP2009538859A (ja) 2006-05-30 2009-11-12 エフ.ホフマン−ラ ロシュ アーゲー ピペリジニルピリミジン誘導体
BRPI0814532A2 (pt) * 2007-07-25 2015-01-27 Hoffmann La Roche Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação dos receptores de h3, e uso desses compostos para a preparação de medicamentos.
CL2008002622A1 (es) 2007-09-06 2009-11-27 Glaxo Group Ltd 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno.
WO2009100120A2 (fr) 2008-02-04 2009-08-13 Neurogen Corporation Pipérazinyl-oxoéthyl-tétrahydropyrazolopyridines substituées par du pyridinyle
CA2719985A1 (fr) 2008-03-31 2009-10-08 Evotec Ag Tetrahydronaphthyridines et ses derives aza a titre d'antagonistes des recepteurs d'histamine h3
WO2009135842A1 (fr) 2008-05-08 2009-11-12 Evotec Neurosciences Gmbh Azétidines et cyclobutanes comme antagonistes des récepteurs h3 de l’histamine
CA2812970C (fr) * 2010-09-02 2015-01-13 Suven Life Sciences Limited Composes heterocyclyle comme ligands des recepteurs h3 de l'histamine

Also Published As

Publication number Publication date
EP2888243B1 (fr) 2016-08-17
EA201590413A1 (ru) 2015-06-30
PL2888243T3 (pl) 2017-01-31
US9328092B2 (en) 2016-05-03
US20150218129A1 (en) 2015-08-06
BR112015001524A2 (pt) 2017-07-04
IL236437A (en) 2016-12-29
EA025136B1 (ru) 2016-11-30
EP2888243A1 (fr) 2015-07-01
MX360001B (es) 2018-10-18
CA2878217C (fr) 2016-05-17
KR101707343B1 (ko) 2017-02-15
AU2012388383B2 (en) 2015-12-10
CY1118035T1 (el) 2017-05-17
CA2878217A1 (fr) 2014-02-27
JP2015526462A (ja) 2015-09-10
JP5981654B2 (ja) 2016-08-31
RS55158B1 (sr) 2017-01-31
CN104540812B (zh) 2016-08-24
AU2012388383A1 (en) 2015-01-22
HK1204620A1 (en) 2015-11-27
SG11201408423XA (en) 2015-01-29
CN104540812A (zh) 2015-04-22
NZ703323A (en) 2016-03-31
ME02519B (fr) 2017-02-20
DK2888243T3 (en) 2016-09-26
SMT201600336B (it) 2016-11-10
WO2014030170A1 (fr) 2014-02-27
LT2888243T (lt) 2016-10-10
MX2015000064A (es) 2015-04-08
PT2888243T (pt) 2016-09-21
AU2012388383C1 (en) 2016-03-17
HRP20161167T1 (hr) 2016-11-04
ES2592819T3 (es) 2016-12-01
KR20150024918A (ko) 2015-03-09
SI2888243T1 (sl) 2016-11-30
BR112015001524B1 (pt) 2022-04-05
HUE030901T2 (en) 2017-06-28
IL236437A0 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
AP2014007810A0 (en) Imidazopyrrolidinone compounds
EP2925129A4 (fr) Composés pro-neurogènes
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2887803A4 (fr) Composés pro-neurogéniques
AP2015008591A0 (en) Heterocyclic compounds
EP2828262A4 (fr) Composés d'imidazotriazinone
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
HK1187613A1 (en) Compounds as histamine h3 receptor ligands h3
GB201209096D0 (en) Compounds
HK1204620A1 (en) Acrylamide compounds as histamine h3 receptor ligands h3
HK1180955A1 (en) Heterocyclyl compounds as histamine h3 receptor ligands h3
GB201217310D0 (en) Compounds
ZA201409244B (en) Acrylamide compounds as histamine h3 receptor ligands
TH1501000921A (th) สารประกอบอะคริลาไมด์ในฐานะลิแกนด์ของฮิสตะมีน h3 รีเซปเตอร์
GB201211308D0 (en) Compounds for use
GB201211086D0 (en) Novel anti-cancer compounds
GB201217311D0 (en) Compounds
GB201217290D0 (en) Compounds
GB201217312D0 (en) Compounds
GB201215284D0 (en) Compounds
TH1401001203B (th) สารประกอบเฮเทอโรเอริลในฐานะที่เป็น 5-ht4 รีเซปเตอร์ลิแกนด์
GB201214250D0 (en) Compounds